

Jean-François EL©ou«t

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5918337/publications.pdf>

Version: 2024-02-01

49
papers

2,428
citations

185998

28
h-index

214527

47
g-index

55
all docs

55
docs citations

55
times ranked

2313
citing authors

#	ARTICLE	IF	CITATIONS
1	Crystal Structure of a Nucleocapsid-Like Nucleoprotein-RNA Complex of Respiratory Syncytial Virus. <i>Science</i> , 2009, 326, 1279-1283.	6.0	290
2	Functional organization of cytoplasmic inclusion bodies in cells infected by respiratory syncytial virus. <i>Nature Communications</i> , 2017, 8, 563.	5.8	141
3	De novo protein design enables the precise induction of RSV-neutralizing antibodies. <i>Science</i> , 2020, 368, .	6.0	137
4	A condensate-hardening drug blocks RSV replication in vivo. <i>Nature</i> , 2021, 595, 596-599.	13.7	121
5	Structure of the Respiratory Syncytial Virus Polymerase Complex. <i>Cell</i> , 2019, 179, 193-204.e14.	13.5	108
6	Visualizing the replication of respiratory syncytial virus in cells and in living mice. <i>Nature Communications</i> , 2014, 5, 5104.	5.8	102
7	Biochemical characterization of the respiratory syncytial virus P and N protein complexes and localization of the P protein oligomerization domain. <i>Journal of General Virology</i> , 2004, 85, 1643-1653.	1.3	94
8	The respiratory syncytial virus nucleoprotein-RNA complex forms a left-handed helical nucleocapsid. <i>Journal of General Virology</i> , 2013, 94, 1734-1738.	1.3	90
9	The nine C-terminal amino acids of the respiratory syncytial virus protein P are necessary and sufficient for binding to ribonucleoprotein complexes in which six ribonucleotides are contacted per N protein protomer. <i>Journal of General Virology</i> , 2007, 88, 196-206.	1.3	82
10	The Respiratory Syncytial Virus M2-1 Protein Forms Tetramers and Interacts with RNA and P in a Competitive Manner. <i>Journal of Virology</i> , 2009, 83, 6363-6374.	1.5	75
11	Structure and Functional Analysis of the RNA- and Viral Phosphoprotein-Binding Domain of Respiratory Syncytial Virus M2-1 Protein. <i>PLoS Pathogens</i> , 2012, 8, e1002734.	2.1	70
12	Interactome Analysis of the Human Respiratory Syncytial Virus RNA Polymerase Complex Identifies Protein Chaperones as Important Cofactors That Promote L-Protein Stability and RNA Synthesis. <i>Journal of Virology</i> , 2015, 89, 917-930.	1.5	65
13	Minimal Elements Required for the Formation of Respiratory Syncytial Virus Cytoplasmic Inclusion Bodies <i>In Vivo</i> and <i>In Vitro</i> . <i>MBio</i> , 2020, 11, .	1.8	65
14	Characterization of a Viral Phosphoprotein Binding Site on the Surface of the Respiratory Syncytial Nucleoprotein. <i>Journal of Virology</i> , 2012, 86, 8375-8387.	1.5	64
15	Identification and Characterization of the Binding Site of the Respiratory Syncytial Virus Phosphoprotein to RNA-Free Nucleoprotein. <i>Journal of Virology</i> , 2015, 89, 3484-3496.	1.5	60
16	Crystal structure of the essential transcription antiterminator M2-1 protein of human respiratory syncytial virus and implications of its phosphorylation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 1580-1585.	3.3	58
17	RSV hijacks cellular protein phosphatase 1 to regulate M2-1 phosphorylation and viral transcription. <i>PLoS Pathogens</i> , 2018, 14, e1006920.	2.1	57
18	A Druggable Pocket at the Nucleocapsid/Phosphoprotein Interaction Site of Human Respiratory Syncytial Virus. <i>Journal of Virology</i> , 2015, 89, 11129-11143.	1.5	56

#	ARTICLE	IF	CITATIONS
19	A Novel Subnucleocapsid Nanoplatfom for Mucosal Vaccination against Influenza Virus That Targets the Ectodomain of Matrix Protein 2. <i>Journal of Virology</i> , 2014, 88, 325-338.	1.5	52
20	New Insights into Structural Disorder in Human Respiratory Syncytial Virus Phosphoprotein and Implications for Binding of Protein Partners. <i>Journal of Biological Chemistry</i> , 2017, 292, 2120-2131.	1.6	49
21	Interferon-Induced Protein 44 and Interferon-Induced Protein 44-Like Restrict Replication of Respiratory Syncytial Virus. <i>Journal of Virology</i> , 2020, 94, .	1.5	49
22	Sub-Nucleocapsid Nanoparticles: A Nasal Vaccine against Respiratory Syncytial Virus. <i>PLoS ONE</i> , 2008, 3, e1766.	1.1	47
23	The Insertion of Fluorescent Proteins in a Variable Region of Respiratory Syncytial Virus L Polymerase Results in Fluorescent and Functional Enzymes But with Reduced Activities. <i>The Open Virology Journal</i> , 2011, 5, 103-108.	1.8	47
24	Fine Mapping and Characterization of the L-Polymerase-Binding Domain of the Respiratory Syncytial Virus Phosphoprotein. <i>Journal of Virology</i> , 2015, 89, 4421-4433.	1.5	45
25	A new subunit vaccine based on nucleoprotein nanoparticles confers partial clinical and virological protection in calves against bovine respiratory syncytial virus. <i>Vaccine</i> , 2010, 28, 3722-3734.	1.7	37
26	A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	35
27	Vaccine Safety and Efficacy Evaluation of a Recombinant Bovine Respiratory Syncytial Virus (BRSV) with Deletion of the SH Gene and Subunit Vaccines Based On Recombinant Human RSV Proteins: N-nanorings, P and M2-1, in Calves with Maternal Antibodies. <i>PLoS ONE</i> , 2014, 9, e100392.	1.1	34
28	A bovine respiratory syncytial virus model with high clinical expression in calves with specific passive immunity. <i>BMC Veterinary Research</i> , 2015, 11, 76.	0.7	30
29	Labyrinthopeptins as virolytic inhibitors of respiratory syncytial virus cell entry. <i>Antiviral Research</i> , 2020, 177, 104774.	1.9	30
30	RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 411-420.	1.7	28
31	The Structure of the Human Respiratory Syncytial Virus M2-1 Protein Bound to the Interaction Domain of the Phosphoprotein P Defines the Orientation of the Complex. <i>MBio</i> , 2018, 9, .	1.8	28
32	Boosting subdominant neutralizing antibody responses with a computationally designed epitope-focused immunogen. <i>PLoS Biology</i> , 2019, 17, e3000164.	2.6	26
33	Biochemical characterization of the respiratory syncytial virus NO-P complex in solution. <i>Journal of Biological Chemistry</i> , 2019, 294, 3647-3660.	1.6	22
34	Non-invasive epicutaneous vaccine against Respiratory Syncytial Virus: Preclinical proof of concept. <i>Journal of Controlled Release</i> , 2016, 243, 146-159.	4.8	21
35	Tetramerization of Phosphoprotein Is Essential for Respiratory Syncytial Virus Budding while Its N-Terminal Region Mediates Direct Interactions with the Matrix Protein. <i>Journal of Virology</i> , 2021, 95, .	1.5	15
36	The Interactome analysis of the Respiratory Syncytial Virus protein M2-1 suggests a new role in viral mRNA metabolism post-transcription. <i>Scientific Reports</i> , 2019, 9, 15258.	1.6	14

#	ARTICLE	IF	CITATIONS
37	The methyltransferase domain of the Respiratory Syncytial Virus L protein catalyzes cap N7 and 2â€™-O-methylation. PLoS Pathogens, 2021, 17, e1009562.	2.1	11
38	Interactions between the Nucleoprotein and the Phosphoprotein of Pneumoviruses: Structural Insight for Rational Design of Antivirals. Viruses, 2021, 13, 2449.	1.5	7
39	Pulmonary mesenchymal stem cells are engaged in distinct steps of host response to respiratory syncytial virus infection. PLoS Pathogens, 2021, 17, e1009789.	2.1	6
40	A Structural and Dynamic Analysis of the Partially Disordered Polymerase-Binding Domain in RSV Phosphoprotein. Biomolecules, 2021, 11, 1225.	1.8	6
41	Depletion of TAX1BP1 Amplifies Innate Immune Responses during Respiratory Syncytial Virus Infection. Journal of Virology, 2021, 95, e0091221.	1.5	6
42	Avian Cell Line DuckCeltâ€™-T17 Is an Efficient Production System for Live-Attenuated Human Metapneumovirus Vaccine Candidate Metavacâ€™. Vaccines, 2021, 9, 1190.	2.1	6
43	First demonstration of the circulation of a pneumovirus in French pigs by detection of anti-swine orthopneumovirus nucleoprotein antibodies. Veterinary Research, 2018, 49, 118.	1.1	5
44	High-throughput screening of active compounds against human respiratory syncytial virus. Virology, 2019, 535, 171-178.	1.1	5
45	Targeting the Respiratory Syncytial Virus N 0 -P Complex with Constrained Î±-Helical Peptides in Cells and Mice. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	5
46	New Look at RSV Infection: Tissue Clearing and 3D Imaging of the Entire Mouse Lung at Cellular Resolution. Viruses, 2021, 13, 201.	1.5	5
47	Hyper-Enriched Anti-RSV Immunoglobulins Nasally Administered: A Promising Approach for Respiratory Syncytial Virus Prophylaxis. Frontiers in Immunology, 2021, 12, 683902.	2.2	5
48	A small fragmented P protein of respiratory syncytial virus inhibits virus infection by targeting P protein. Journal of General Virology, 2020, 101, 21-32.	1.3	5
49	Characterization of the Interaction Domains between the Phosphoprotein and the Nucleoprotein of Human Metapneumovirus. Journal of Virology, 2022, 96, JVI0090921.	1.5	4